New Zealand markets open in 5 hours 1 minute

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
66.95-4.15 (-5.84%)
As of 10:58AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 7.44B
Enterprise value 7.00B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.53
Price/book (mrq)15.85
Enterprise value/revenue 10.85
Enterprise value/EBITDA -18.23

Trading information

Stock price history

Beta (5Y monthly) 1.25
52-week change 3-26.55%
S&P500 52-week change 322.74%
52-week high 3103.34
52-week low 365.30
50-day moving average 384.37
200-day moving average 379.53

Share statistics

Avg vol (3-month) 3962.6k
Avg vol (10-day) 31.55M
Shares outstanding 587.08M
Implied shares outstanding 6N/A
Float 883.19M
% held by insiders 14.41%
% held by institutions 175.57%
Shares short (30 Dec 2021) 44.58M
Short ratio (30 Dec 2021) 45.69
Short % of float (30 Dec 2021) 46.08%
Short % of shares outstanding (30 Dec 2021) 45.26%
Shares short (prior month 29 Nov 2021) 45.45M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 311 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin -75.30%
Operating margin (ttm)-79.70%

Management effectiveness

Return on assets (ttm)-11.82%
Return on equity (ttm)-71.40%

Income statement

Revenue (ttm)645.56M
Revenue per share (ttm)8.12
Quarterly revenue growth (yoy)31.60%
Gross profit (ttm)-245.53M
EBITDA -479.35M
Net income avi to common (ttm)-486.12M
Diluted EPS (ttm)-6.11
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.6B
Total cash per share (mrq)18.36
Total debt (mrq)1.18B
Total debt/equity (mrq)250.76
Current ratio (mrq)5.85
Book value per share (mrq)5.87

Cash flow statement

Operating cash flow (ttm)-588.38M
Levered free cash flow (ttm)-265.04M